Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price target upped by HC Wainwright from $48.00 to $50.00 in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently weighed in on HALO. TheStreet downgraded shares of […]